Valeritas (OTCMKTS:VLRXQ) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.
This table compares Valeritas and Sintx Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for Valeritas and Sintx Technologies, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valeritas presently has a consensus target price of $1.50, suggesting a potential upside of 9,900.00%. Sintx Technologies has a consensus target price of $2.25, suggesting a potential upside of 15.98%. Given Valeritas’ higher probable upside, equities research analysts clearly believe Valeritas is more favorable than Sintx Technologies.
Valuation & Earnings
This table compares Valeritas and Sintx Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Valeritas||$26.40 million||0.00||-$45.93 million||N/A||N/A|
|Sintx Technologies||$690,000.00||33.85||-$4.80 million||N/A||N/A|
Sintx Technologies has lower revenue, but higher earnings than Valeritas.
Risk and Volatility
Valeritas has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
Insider and Institutional Ownership
3.8% of Valeritas shares are held by institutional investors. Comparatively, 0.9% of Sintx Technologies shares are held by institutional investors. 1.0% of Valeritas shares are held by company insiders. Comparatively, 0.3% of Sintx Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valeritas beats Sintx Technologies on 7 of the 13 factors compared between the two stocks.
Valeritas Company Profile
Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.
Sintx Technologies Company Profile
Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. The company offers ceramic based biomaterial solutions in various medical and industrial applications. It provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. The company markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. Sintx Technologies, Inc. has a collaboration agreement with CTL Amedica to design and launch spinal implants. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.